Skip to main content
Clinical Trials/NCT05277441
NCT05277441
Unknown
Not Applicable

A Novel Classification for the Assessment and Grading of Unexpected Events in Pediatric Surgery: The Clavien-Madadi Classification

Hannover Medical School1 site in 1 country10,000 target enrollmentStarted: January 1, 2017Last updated:

Overview

Phase
Not Applicable
Enrollment
10,000
Locations
1
Primary Endpoint
Incidence of adverse events

Overview

Brief Summary

Postoperative adverse events may be associated with substantial morbidity and mortality. However, inconsistent definitions of complications and unexpected events have limited accurate analysis of surgical outcomes. In 2004, the Clavien-Dindo classification for postoperative complications has been introduced and has since then been validated in numerous studies, with more than 20.000 citations.

Despite the appraisal of the Clavien-Dindo classification in the pediatric surgical literature, some criticize the transfer of grading systems for adults into a pediatric cohort without modification or validation. In a recent study we have shown that few items of the classification do not offer relevant information in pediatric cohorts and we have added organizational and management errors, not integrated in the initial proposal by Dindo et al. Especially, the variety of options for the management of complications based on institutional protocols and logistics is emphasized and a more focused and detailed assessment of the invasiveness of procedures in children is introduced.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
0 Years to 18 Years (Child, Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • All patients with unexpected events within the study period, treated at the department of pediatric surgery (preterms - 17 years of age), Hannover Medical School

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Incidence of adverse events

Time Frame: Through study completion, an average of 3 years

Secondary Outcomes

  • Classification of adverse events(Through study completion, an average of 3 years)
  • Classification of adverse events using a novel instrument(Through study completion, an average of 3 years)
  • Categorization of adverse events(Through study completion, an average of 3 years)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Omid Madadi-Sanjani, Dr.

Principal investigator, Consultant Pediatric Surgery

Hannover Medical School

Study Sites (1)

Loading locations...

Similar Trials